Literature DB >> 21055733

Human breast tumor cells express IL-10 and IL-12p40 transcripts and proteins, but do not produce IL-12p70.

Mark C Heckel1, Alexey Wolfson, Christopher A Slachta, Roland Schwarting, Padmini Salgame, Christos D Katsetos, Chris D Platsoucas.   

Abstract

IL-10 transcripts were expressed in 14/15 primary breast adenocarcinomas and in 5/8 established breast tumor lines. Immunohistochemistry and immunoprecipitation from lysates and supernatants revealed that established breast tumor lines produced IL-10 protein. Immunohistochemistry revealed that IL-10 is localized to tumor cells of primary breast adenocarcinomas and to occasional infiltrating MNC. Established breast tumor cell lines expressed IL-12p40 transcripts (6/8) and protein (4/7) and IL-12p35 transcripts (6/7). Using two sandwich ELISAs, specific, respectively, for IL-12p40 and IL-12p70 proteins, we demonstrated that established breast tumor cell lines produce IL-12p40 monomer/homodimer, but not IL-12p70. Positive staining for IL-12p70 in primary breast adenocarcinomas was found only in MNC infiltrating the tumor while tumor cells were negative. IL-12p40 homodimer/monomer inhibit as antagonists IL-12 or IL-23, although they may also act as agonists and positive regulators. Also, primary breast adenocarcinomas (15/15) and established breast tumor cell lines (6/8) expressed TGF-β1 transcripts. IL-10, IL-12p40 and TGF-β1 may inhibit substantially the anti-tumor immune response.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21055733     DOI: 10.1016/j.cellimm.2010.09.010

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  18 in total

1.  The Influence of Biomaterials on Cytokine Production in 3D Cultures.

Authors:  Mary C Regier; Sara I Montanez-Sauri; Michael P Schwartz; William L Murphy; David J Beebe; Kyung Eun Sung
Journal:  Biomacromolecules       Date:  2017-02-16       Impact factor: 6.988

2.  Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma.

Authors:  Chen Cai; Jin Zhang; Minyu Li; Zhen-Jie Wu; Ken H Song; Tina W Zhan; Lin-Hui Wang; Ying-Hao Sun
Journal:  Tumour Biol       Date:  2015-12-30

3.  Regulation of IL-12p40 by HIF controls Th1/Th17 responses to prevent mucosal inflammation.

Authors:  E Marks; C Naudin; G Nolan; B J Goggins; G Burns; S W Mateer; J K Latimore; K Minahan; M Plank; P S Foster; R Callister; M Veysey; M M Walker; N J Talley; G Radford-Smith; S Keely
Journal:  Mucosal Immunol       Date:  2017-01-25       Impact factor: 7.313

Review 4.  Innate immune cells in breast cancer--from villains to heroes?

Authors:  Tim Kees; Mikala Egeblad
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-07-26       Impact factor: 2.673

5.  Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosisin breast cancer.

Authors:  Guanghui Chen; Yanfang Liang; Xin Guan; Hui Chen; Qiankun Liu; Bihua Lin; Can Chen; Mingyuan Huang; Jianan Chen; Weiquan Wu; Yi Liang; Keyuan Zhou; Jincheng Zeng
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

6.  Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis?

Authors:  Hemanga Kumar Bhattacharjee; Virinder Kumar Bansal; Bikash Nepal; Sandeep Srivastava; Amit K Dinda; Mahesh C Misra
Journal:  Indian J Surg Oncol       Date:  2016-02-20

7.  Medroxyprogesterone acetate differentially regulates interleukin (IL)-12 and IL-10 in a human ectocervical epithelial cell line in a glucocorticoid receptor (GR)-dependent manner.

Authors:  Renate Louw-du Toit; Janet P Hapgood; Donita Africander
Journal:  J Biol Chem       Date:  2014-09-08       Impact factor: 5.157

8.  Esmolol inhibits inflammation and apoptosis in the intestinal tissue via the overexpression of NF-κB-p65 in the early stage sepsis rats.

Authors:  Chang-An Guo; Li Ma; Xiao-Lu Su; Ying-Zhen Wang; Ling-Ling Zhen; Bei Zhang; Hong An; Hong-Bin Liu
Journal:  Turk J Gastroenterol       Date:  2020-04       Impact factor: 1.852

9.  Monitoring regulatory immune responses in tumor immunotherapy clinical trials.

Authors:  Brian M Olson; Douglas G McNeel
Journal:  Front Oncol       Date:  2013-05-06       Impact factor: 6.244

10.  Thwarting galectin-induced immunosuppression in breast cancer.

Authors:  Mariana Salatino; Tomas Dalotto-Moreno; Gabriel A Rabinovich
Journal:  Oncoimmunology       Date:  2013-05-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.